49 results on '"Carson, W.H."'
Search Results
2. Symptoms and functioning in aripiprazole once-monthly maintenance treatment of bipolar I disorder: a blinded, placebo-controlled, randomised study
3. P.2.d.030 - Symptoms and functioning in aripiprazole once-monthly maintenance treatment of bipolar I disorder: a blinded, placebo-controlled, randomised study
4. P.2.d.027 - Recurrence and recovery in aripiprazole once-monthly maintenance treatment of bipolar I disorder: a blinded, placebo-controlled, randomised study
5. P.3.d.079 Brexpiprazole (OPC-34712) efficacy and safety as maintenance therapy in adults with schizophrenia: Randomised, double-blind, placebo-controlled study
6. Functional Outcomes with Aripiprazole Once-Monthly in Two Double-Blind, Placebo- and Active-Controlled Studies (Aspire US 246 and Aspire EU 247) for the Treatment of Schizophrenia
7. P.3.d.027 Aripiprazole once-monthly for schizophrenia: a double-blind, randomised, non-inferiority study versus oral aripiprazole
8. P.3.d.028 Personal and social performance in schizophrenia: double-blind, non-inferiority study of once-monthly vs oral aripiprazole
9. 2277 – A placebo-controlled study of efficacy and safety of aripiprazole once-monthly for long-term maintenance treatment in schizophrenia
10. 2281 – Psychosocial and overall effectiveness of aripiprazole once-monthly vs. placebo once-monthly for maintenance treatment in schizophrenia
11. 2288 – A 12-week, randomized, placebo-controlled study evaluating the efficacy and safety of aripiprazole in combination with lithium/valproate inpartially-responsive bipolar mania
12. P.3.c.018 A placebo-controlled study of efficacy/safety of aripiprazole intramuscular depot for long-term maintenance treatment of schizophrenia
13. P.3.c.019 Psychosocial and overall effectiveness of aripiprazole intramuscular depot vs. placebo for maintenance treatment in schizophrenia
14. PW01-60 - Similar Short- And Long-Term Efficacy Results Of Aripiprazole In Post-Pubertal Adolescents (Ages 15-17) And Adults With Schizophrenia
15. P.7.c.003 Somnolence and sedation in adolescents with schizophrenia treated with aripiprazole (acute and long term follow-up)
16. P.7.C.002 Effects of aripiprazole on glucose, lipids and weight in adolescent patients: a pooled analysis of 2 clinical trials
17. Aripiprazole monotherapy in the treatment of acute bipolar I mania: A randomized, double-blind, placebo- and lithium-controlled study
18. P.7.a.005 Long-term efficacy and safety of aripiprazole in children and adolescents with mania
19. Long-term efficacy and safety of Aripiprazole in children (10-17 yo) with mania
20. Efficacy and tolerability of aripiprazole in adolescents with schizophrenia
21. 22 – Acute efficacy of aripiprazole for the treatment of bipolar I disorder in pediatric patients
22. 21– A 6-week study of the efficacy and tolerability of aripiprazole in pediatric patients with schizophrenia
23. P.7.a.003 Efficacy of aripiprazole in the treatment of adolescents with schizophrenia
24. P.3.c.051 Aripiprazole maintenance therapy in bipolar disorder: a placebo-controlled, 74-week extension of a 26-week study (CN138-010)
25. Aripiprazole in child and adolescent psychiatric disorders: Safety, tolerability, and pharmacokinetics
26. Aripiprazole in child and adolescent psychiatric disorders: Effectiveness preliminary report
27. Long-term efficacy of aripiprazole to treat psychosis in schizophrenia: Sub-analysis of two double-blind, haloperidol controlled studies
28. P.3.c.046 Effectiveness of aripiprazole versus olanzapine, quetiapine, or risperidone: sub-analysis of a large, randomized, naturalistic study (STAR)
29. P.3.c.028 Effectiveness of aripiprazole versus standard of care treatment in patients with schizophrenia: the Schizophrenia Trial of Aripiprazole (STAR) study
30. Meta-analysis of the efficacy of aripiprazole in schizophrenia
31. Safety and tolerability meta-analysis of aripiprazole in schizophrenia
32. Meta-analysis of weight effects with aripiprazole
33. Safety and tolerability of aripiprazole in patients with schizophrenia stratified by race
34. Aripiprazole in patients with first episode schizophrenia
35. Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder
36. Reduction in negative symptoms of schizophrenia during long-term therapy with aripiprazole
37. Aripiprazole versus placebo in acute mania
38. Aripiprazole for long-term maintenance treatment of schizophrenia
39. Atypical antipsychotic adherence and hospitalization in patients with schizophrenia
40. Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia
41. Meta-analysis of the efficacy of aripiprazole in schizophrenia
42. Neurocognitive effects: aripiprazole vs olanzapine in stable psychosis
43. Controlled study of aripiprazole and haloperidol in schizophrenia
44. Safety and tolerability meta-analysis of aripiprazole in schizophrenia
45. Aripiprazole and risperidone versus placebo in schizophrenia
46. Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: Results of a placebo-controlled trial with risperidone
47. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo
48. PMH50 - Functional Outcomes with Aripiprazole Once-Monthly in Two Double-Blind, Placebo- and Active-Controlled Studies (Aspire US 246 and Aspire EU 247) for the Treatment of Schizophrenia
49. PMH50 Functional Outcomes with Aripiprazole Once-Monthly in Two Double-Blind, Placebo- and Active-Controlled Studies (Aspire US 246 and Aspire EU 247) for the Treatment of Schizophrenia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.